3-氨基-1H-吡咯-2-甲酸乙酯 | 252932-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 3-氨基-1H-吡咯-2-甲酸乙酯
• 中文别名: 3-氨基-1H-吡咯-2-羧酸乙酯
• 英文名称: 3-amino-2-ethoxycarbonylpyrrole
• 英文别名: ethyl 3-amino-1H-pyrrole-2-carboxylate
• CAS: 252932-48-2
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD06797655
• 分子量: 154.169
• InChiKey: SPNDLEQTZLQLTA-UHFFFAOYSA-N

物化性质

• 沸点：
  310.9±22.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  68.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-amino-1H-pyrrole-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-amino-1H-pyrrole-2-carboxylate
CAS number: 252932-48-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2
Molecular weight: 154.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-1H-吡咯-2-甲酸乙酯 在 potassium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 8.08h， 生成 pyrrolo[3,2-d][1,3]oxazine-2,4(1H,5H)-dione
  参考文献：
  名称：

  吡咯并[3,2- d ] [1,3]恶嗪-2,4-二酮的合成与反应性。获得新的吡咯并[3,2- e ] [1,4]二氮杂-2,5-二酮

  摘要：

  描述了一种方便合成吡咯并[3,2- d ] [1,3]恶嗪-2,4-二酮4的方法，并研究了其对各种亲核试剂的反应性。在丙氨酸或脯氨酸存在下，酸酐4或其N-烷基化类似物25的区域选择性开环分别提供了咪唑烷二酮22和N-保护的吡咯并[3,2- e ] [1,4]二氮杂卓30和31。一锅法。在这项研究的最后一部分中，提供了另一种途径来生产八个未保护的吡咯并[3,2- e ] [1,4]二氮杂-2,5-二酮35a – h的文库描述了克服酸酐4的有限反应性的方法。

  DOI：

  10.1016/j.tet.2014.05.046
• 作为产物：
  描述：

  diethyl 2-((2-cyanovinyl)amino)malonate 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 120.0h， 生成 3-氨基-1H-吡咯-2-甲酸乙酯
  参考文献：
  名称：

  新型取代的嘌呤等排体：合成、构效关系和细胞毒活性评估

  摘要：

  设计和合成了许多吡咯并[2,3-c]吡啶、吡咯并[3,2-d]嘧啶和吡唑并[4,3-d]嘧啶作为抗增殖剂。目标化合物在中央支架上的相似位置具有选定的取代基，可以提取有趣的 SAR。新衍生物对前列腺 (PC-3) 和结肠 (HCT116) 细胞系的细胞毒活性进行了评估，最有效的类似物显示出从 nM 到低 µM 范围内的 IC50 值，而发现它们对正常人成纤维细胞（WI-38）。DNA 含量的流式细胞术分析显示，最有希望的衍生物 14b 在 G2/M 期引起 PC-3 细胞的统计学显着积累，并诱导 PC-3 细胞凋亡。

  DOI：

  10.3390/molecules27010247
• 作为试剂：
  描述：

  3-氨基-1H-吡咯-2-甲酸乙酯 、 Isopropyloxyacetaldehyd 在 3-氨基-1H-吡咯-2-甲酸乙酯 作用下， 以58的产率得到3-[(2-isopropoxyethyl)amino]-1H-pyrrole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy

  摘要：

  公开了式（I）的新化合物，其中R1，R12，L，X和Y如规范中所定义，并且其药学上可接受的盐;以及它们的制备过程，含有它们的组合物以及它们在治疗中的用途。这些化合物是MPO酶的抑制剂，因此在治疗或预防神经炎症性疾病，心血管疾病和呼吸系统疾病方面特别有用。

  公开号：

  US07829707B2

文献信息

• THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS
  申请人：Gupta Varsha

  公开号：US20120095016A1

  公开（公告）日：2012-04-19

  The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA A receptor and negatively modulating the α5 subtype of GABA A , and use of the compound of formula I in the manufacture of a medicament for the treatment of GABA A receptor associated disorders. The invention further provides a method of modulation of one or more GABA A subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

  这项发明提供了一种新颖的化学系列，其化学式为I，以及利用该化合物结合到GABA A 受体的苯二氮卓位点并负性调节GABA A 的α5亚型的方法，以及利用化合物I的制备药物治疗GABA A 受体相关疾病的方法。该发明还提供了一种在动物体内调节一个或多个GABA A 亚型的方法，包括向动物体内施用化合物I的有效量。
• AROMATIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1956009A1

  公开（公告）日：2008-08-13

  An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

  以下公式表示的芳香族化合物或其药用可接受盐： 其中，环A是杂环，环B是碳环、杂环等，G1、G2、G3、G4和G5是CH或N，X是-NH-、-O-、-CH2-等，Y是-CH2-、-CO-、-SO2-等，Z是单键、-CO-、-SO2-、-NH-、-O-、-S-、-CONH-、-SO2NH-等，R2是氢、烷基、烷氧基、卤素等，R3是碳环组、杂环组、烷基等， 作为控制CCR4功能的调节剂，对治疗或治疗支气管哮喘、特应性皮炎等疾病很有用。
• ALICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1970373A1

  公开（公告）日：2008-09-17

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下是该公式表示的脂环杂环化合物或其药用可接受盐： 其中环A是杂环，环B是碳环，杂环等，P1和P2是CH或N，q和r为0至2，X为-NH-，-O-，-CH2-等，Y为-CH2-，-CO-，-SO2-等，Z为-CO-，-SO2-等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基， 可用作CCR4功能的控制剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• [EN] ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE<br/>[FR] RÉACTIONS ORGANIQUES RÉALISÉES DANS UNE SOLUTION AQUEUSE EN PRÉSENCE D'UNE HYDROXYALKYL(ALKYL)CELLULOSE OU D'UNE ALKYLCELLULOSE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2017129796A1

  公开（公告）日：2017-08-03

  The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.

  本发明涉及在水溶液中在羟基烷基（烷基）纤维素或烷基纤维素存在下进行有机反应的方法。
• Fused ring compound and use thereof
  申请人：Suzuki Hideo

  公开号：US20100190747A1

  公开（公告）日：2010-07-29

  The present invention provides a compound represented by the formula: wherein the symbols are as described in the specification, or a salt thereof, which is useful for preventing/treating eicosanoid-associated diseases such as atherosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis and atopic dermatitis, and which has an excellent pharmacological action, physicochemical properties, etc.

  本发明提供一种化合物，其化学式如下： 其中符号如规范中所述，或其盐，用于预防/治疗与前列腺素相关的疾病，如动脉粥样硬化、糖尿病、肥胖、动脉血栓形成、哮喘、发热、疼痛、癌症、风湿病、骨关节炎和特应性皮炎等，并具有优异的药理作用、理化性质等。